Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

SATURN Secretome bAsed Therapy for complex perianal fistUlas in CRohN’s disease

Coordinator
Everzom, France
Runs
1 October 2026 to 30 September 2031
Status
Running
EU funding
€13.3m
Total cost
€13.3m
Partners
16 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101290269

What the project is doing

In the project's own words, from its summary on CORDIS.

SATURN aims to demonstrate the safety and efficacy of EVerGel, a mesenchymal stem cell–derived extracellular vesicle–enriched secretome (MSC-EV-Se) therapy, through phase I and II clinical trials in patients with complex perianal fistulas (CPF) in Crohn’s disease. EVerGel is a dual formulation of MSC-EV-Se: a PBS solution injected subcutaneously to modulate perilesional inflammation, and injected in a thermosensitive intraluminal hydrogel to support tract closure, ensure optimal biodistribution? and provide sustained drug release.

This approach aims to improve healing in CPF refractory to anti-TNF therapies. Multicenter, randomized, placebo-controlled phase I and II clinical trials will be conducted in France, Spain, and Italy. The project addresses key bottlenecks of secretome-based therapies. A GMP-compliant, scalable, and standardized manufacturing process has already been established for clinical batches, and a potency testing matrix will be created through characterization of bioactive factors.

Longitudinal analyses of patient biopsies and fluids with multi-omics, imaging, and functional assays will map immune modulation and tissue repair pathways, offering insights into the mode of action and informing future patient stratification. To achieve these objectives, a 15-partner consortium across 5 European countries (France, Spain, Germany, Italy, and Belgium), coordinated by EVerZom (France), gathers leading clinical centers (II-FJD Madrid, ICH Milan, AP-HM Marseille), EV/secretome research labs (Université de Nantes, Univ. of Essen), manufacturing experts (EFS and INITS, France), a clinical operations network (ECRIN, France), a patient association (EFFCA, Belgium), and a regulatory CRO (Revio, Spain).

The project will deliver a standardized, regulatory-ready secretome product with initial clinical validation, interoperable assays, and reference materials, and a clear path to phase III evaluation in a high-burden indication

Topics

Who is involved

OrganisationCityCountryRole
EverzomParisFranceCoordinator
International Federation of Crohn's and Ulcerative Colitis AssociationsBruxelles / BrusselBelgiumParticipant
Universitaetsklinikum EssenEssenGermanyParticipant
Fundacion Para La Gestion De La Investigacion En Salud De SevillaSevillaSpainThird party
Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La PazMadridSpainThird party
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainThird party
Instituto Investigacion Sanitaria Fundacion Jimenez DiazMadridSpainParticipant
Revio Pharmaceutical Consultants SLMadridSpainParticipant
Centre Hospitalier Regional De Marseille Assistance Publique-Hopitaux MarseilleMarseille Cedex 20FranceParticipant
Centre Hospitalier Universitaire De NantesNantesFranceThird party
Ecrin European Clinical Research Infrastructure NetworkParisFranceParticipant
Etablissement Francais Du SangLa Plaine Saint DenisFranceParticipant
Inits SmoMontpellierFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Nantes UniversiteNantesFranceParticipant
Humanitas Mirasole SpARozzano (Mi)ItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI